The SURMOUNT-5 head-to-head trial directly compared tirzepatide to semaglutide and found 47% greater weight loss with tirzepatide at 72 weeks
Isolating variables quickly reveals repeatable triggers
[8] [18] Whilst nausea is a common class effect of GLP-1 receptor agonists, it's important to distinguish normal, expected nausea from symptoms that require medical attention
The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use
Many metabolic changes begin to occur, which can lead to greater risk for heart disease, diabetes, metabolic syndrome